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Abstract: 
Aims/Hypothesis: Better understanding of type 2 diabetes and its prevention is a pressing need. 
Changes in human plasma N-glycome are associated with many diseases and represent 
promising diagnostic and prognostic biomarkers. Variations in glucose metabolism directly 
affect glycosylation through the hexosamine pathway, but studies of plasma glycome in type 2 
diabetes are scarce. 
Methods: Using chromatographic approach, we analysed N-linked glycans from plasma proteins 
in two populations comprising individuals with registered hyperglycaemia during critical illness 
(increased risk for development of type 2 diabetes) and individuals who stayed normoglycaemic 
during the same condition -  AcuteInflammation (59 cases vs. 49 controls) and 
AcuteInflammation Replication (52 cases vs. 14 controls) populations. Additionally, N-glycome 
was also studied in individuals from FinRisk (37 incident cases of type 2 diabetes collected at 
baseline vs 37 controls), ORCADES (94 individuals with HbA1c > 6.5 % (47.5 mmol/mol) vs 
658 controls) and SABRE cohort studies (307 individuals with HbA1c > 6.5 % (47.5 mmol/mol) 
vs 307 controls). 
Results: Individuals with increased risk for diabetes type 2 development (AcuteInflammation 
and AcuteInflammation Replication populations), incident cases of type 2 diabetes collected at 
baseline (FinRisk population) and individuals with elevated HbA1c (ORCADES and SABRE 
populations) all presented increased branching, galactosylation and sialylation of plasma protein 
N-glycans and these changes were of similar magnitude. 
Conclusions/Interpretation: Increased complexity of plasma N-glycan structures is associated 
with higher risk of developing type 2 diabetes and poorer regulation of blood glucose levels. 
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Although further research is needed, this finding could offer a potential new approach for 
improvement in prevention of diabetes and its complications. 
 
Keywords: diabetes predisposition; hyperglycaemia; N-linked glycans; plasma N-glycome; type 
2 diabetes; 
 
Abbreviations 
2-AB - 2-aminobenzamide; ACN - acetonitrile; AI - AcuteInflammation; AI_R - 
AcuteInflammation Replication; BEH - bridged ethylene hybrid; BMI - Body Mass Index; CI - 
confidence interval; DMSO - dimethyl sulfoxide; FIN - FinRisk; G0 - agalactosylated; G1 - 
monogalactosylated; G2 - digalactosylated; G3 - trigalactosylated; G4 - tetragalactosylated; 
GlcNAc - N-acetylglucosamine; HB - high branching; HG - hyperglycaemia; HILIC - 
hydrophilic interaction liquid chromatography; ICU - intensive care unit; LB - low branching; 
OGTT - oral glucose tolerance test; ORK - ORKNEY; PNGase F - N-glycosidase F; RR - 
relative risk; S0 - not sialylated; S1 - monosialylated; S2 - disialylated; S3 - trisialylated, S4 - 
tetrasialylated; SAB - SABRE; SDS - sodium dodecyl sulfate; SE - standard error; UDP - uridine 
diphosphate; UPLC - ultra performance liquid chromatography;  
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Introduction 
Type 2 diabetes represents one of the major public health challenges globally, having a 
constantly growing prevalence with the global projection of 7.3 % for the year 2025 [1]. 
Intensive research in the past decades resulted in the introduction of new oral and parenteral 
medications that may improve the management of the disease. However, recognising individuals 
with increased risk of type 2 diabetes development is of equal importance, since many potential 
interventions are available which can postpone and maybe even prevent the disease onset.  
It has been recently shown that individuals without a history of diabetes, who developed 
hyperglycaemia (plasma glucose > 7.7 mmol/L) during critical illness are at significantly 
increased risk of developing type 2 diabetes [2, 3]. The relative risk (RR) of type 2 diabetes 
development during five years after the acute illness was 5.6 (95% confidence interval (CI) 3.1, 
10.2). The phenomenon probably arises from the fact that people who develop hyperglycaemia 
in critical illness already have a latent disorder in glycaemic control. This disorder cannot be 
detected with the usual screening tests, but manifests in the circumstances of severe acute illness 
due to inflammatory and stress mediators. Individuals without this latent disorder manage to 
overcome hyperglycaemic effects of stress, and inflammation and remain normoglycaemic.  
After the acute illness subsides, individuals who presented with hyperglycaemia become 
normoglycaemic again, but the underlying disorder in glucose metabolism apparently makes 
them prone to type 2 diabetes development.  
Glycosylation is the most frequent co- and post-translational modification of proteins, 
which in many cases modulates their function [4]. Contrary to glycation (which is a non-
enzymatic chemical reaction), this highly complex enzymatic process is strictly regulated by the 
network of many enzymes, transcriptional factors, sugar nucleotides and other molecules [5]. 
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Although proteins possess well defined glycosylation sites, a great heterogeneity of their glycans 
exists. Human plasma N-glycome is quite stable within the individual [6], but is extremely 
sensitive to pathophysiological processes, reflecting  the cell state from the time of protein 
secretion [7]. The main diagnostic deficit of glycans is in their low specificity, thus they are more 
frequently studied as prognostic and stratification markers. Their great variability within 
population, and the significant heritability rate, gives them a great potential in risk assessments. 
Changes in glycosylation of plasma proteins have been studied in many different diseases, 
including type 2 diabetes mellitus [8]. These changes have been confirmed in both patients with 
diabetes and db/db mice [9, 10]. Although many studies identified biantennary glycans with core 
fucose as structures of main interest, differences between cases and healthy population were 
never pronounced enough to have a diagnostic potential, probably as a result of relatively good 
glycaemic control in patients, administration of medicaments or existence of many different 
molecular mechanisms that lead to type 2 diabetes development.  
The aim of this study was to determine whether plasma protein N-glycome is changed in 
individuals who are at greater risk of developing type 2 diabetes, using three different 
populations: 
1. Two populations including individuals with registered hyperglycaemia in critical illness 
(increased risk for development of type 2 diabetes) and individuals with normoglycaemia 
in critical illness -  AcuteInflammation  and AcuteInflammation Replication populations; 
2. Individuals who developed type 2 diabetes during 10 years follow-up and those who 
remained normoglycaemic - FinRisk population.  
Also, to further confirm the connection of changes in N-glycome with glucose metabolism 
disruption, we used data from our previous plasma protein glycosylation analysis in two other 
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cohorts (ORCADES and SABRE), where we separated age- and sex-matched individuals into 
two subgroups differing in HbA1c status (HbA1c < 6.5 % (47.5 mmol/mol) and HbA1c > 6.5 % 
(47.5 mmol/mol)).  
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Study populations and methods 
Patients with/without hyperglycaemia during critical illness (AcuteInflammation and 
AcuteInflammation Replication populations) 
AcuteInflammation population - We included patients from a medical intensive care unit 
(ICU) at the University Hospital Centre Zagreb during a period of 6 months (February to July 
2013). Adult (>18 years old) patients with negative history of diabetes who were admitted to the 
ICU and discharged from the hospital alive were eligible for inclusion. Excluded were patients 
diagnosed with diabetes or impaired glucose tolerance and/or impaired fasting glucose before or 
during hospitalization, patients with documented gestational diabetes, pregnant patients and 
patients taking glucocorticoids during or 3 months before the admission. Informed consent 
process was conducted by a member of the study team at the discharge from the ICU or the 
hospital. Consenting patients were asked to attend a follow-up appointment, 6-8 weeks after the 
hospital discharge. At this visit inclusion/exclusion criteria were confirmed. Complete blood 
count and CRP were determined to exclude persisting inflammatory process. Patients with 
elevated markers of inflammation were retested after 2 weeks. All patients underwent oral 
glucose tolerance test (OGTT) and measurement of HbA1c to identify pre-existing diabetes. ADA 
criteria for diagnosis of diabetes were employed and patients diagnosed with existing pre-
diabetes or diabetes were excluded. Height, weight and BMI were recorded; family history of 
diabetes was documented. For all patients fasting blood samples for N-glycan profiling were 
collected in tubes with anticoagulants (both EDTA and citrate for each patient), plasma was 
separated immediately and stored at -20°C until the analysis. For each patient, samples were 
analysed in duplicates. In total, 108 patients were enrolled in the study. 
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AcuteInflammation Replication population - All cardiac surgical patients operated at the 
University Hospital Centre Zagreb (cardiac surgical procedures employing cardiopulmonary 
bypass) from October 2010 to February 2011 and discharged from the hospital alive were 
screened for the study. All individuals provided written informed consent. Excluded were 
patients diagnosed with diabetes or impaired glucose tolerance and/or impaired fasting glucose 
before or during hospitalization. In total, 66 patients were enrolled in the study and from all of 
them blood was drawn on the day of the surgery, before the surgical procedure. The blood 
samples were collected in tubes containing EDTA, plasma was separated and stored at -20°C 
until analysis.  
Relevant demographic data for both populations are summarized in Table 2. 
 
Individuals who did/did not develop T2D within 10 years from sampling (FinRisk study) 
Plasma samples, stored at - 70°C, collected through the study designed to investigate risk 
factors in Finland population [11] were used. Population data were searched for patients with 
incident type 2 diabetes after 10 years follow-up. Individuals who developed any autoimmune, 
malignant or other chronic disease were excluded. Thirty-seven individuals (aged 60 (34, 72)), 
who developed type 2 diabetes and no other chronic disease, were identified and included in this 
study. Thirty-seven age and sex matching controls (age 61 (35, 73)), who remained healthy 
during the follow-up period, were selected from the same population. 
 
Individuals with different HbA1c status (ORCADES and SABRE studies) 
Plasma samples from the Orkney Complex Disease Study (ORCADES), collected in 
Scottish archipelago of Orkney, between 2005 and 2011 [12] as well as fromSABRE population 
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were used [13]. Data on age, sex and HbA1c levels were included in the study. Glycan data for 
aforementioned population had been obtained for another purpose, but was used in this study to 
compare N-glycomes of individuals with HbA1c < 6.5 % (47.5 mmol/mol) and HbA1c > 6.5 % 
(47.5 mmol/mol). From Orkney population glycan and HbA1c data for 752 individuals aged 18 to 
100 years from a subgroup of ten islands were used for this analysis. Consecutively, 658 
individuals (aged 63 (18, 97)) were identified as having HbA1c < 6.5 % (47.5 mmol/mol) and 94 
(aged 63 (19, 88)) as having HbA1c > 6.5 % (47.5 mmol/mol). From SABRE population, data for 
307 individuals (aged 70 (60, 84)) with HbA1c < 6.5 % (47.5 mmol/mol) and 307 (aged 70 (60, 
84)) with HbA1c > 6.5 % (47.5 mmol/mol) were included. 
All studies are supported by written informed consent from all individuals and approvals 
from eligible local Ethics Committees.   
Glycan analysis 
Glycan release and labelling - Prior to analysis, all samples (cases and controls) have 
been randomized throughout the multi-well plates. For each plate 4 standards (pool of plasma 
samples) have been added to minimize the experimental error.  Each plasma sample (10 μL) was 
denatured with the addition of 20 μL of 2 % SDS (w/v) (Invitrogen, Carlsbad, CA, USA) and by 
incubation at 65 °C for 10 min. Subsequently, 10 μL of 4 % Igepal-CA630 (Sigma-Aldrich, St. 
Louis, MO, USA) and 1.25 mU PNGase F (ProZyme, Hayward, CA, USA) in 10 μL 5× PBS 
were added. The samples were incubated overnight at 37 °C for N-glycan release. The released 
N-glycans were labelled with 2-aminobenzamide (2-AB). The labelling mixture was freshly 
prepared by dissolving 2-AB (19.2 mg/mL, Sigma-Aldrich, St. Louis, MO, USA) and 2-picoline 
borane (44.8 mg/mL, Sigma-Aldrich, St. Louis, MO, USA) in DMSO (Sigma-Aldrich, St. Louis, 
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MO, USA) and glacial acetic acid (Merck, Darmstadt, Germany) mixture (70:30, v/v). Labelling 
mixture (25 μL) was added to each N-glycan sample in the 96-well plate, which was then sealed 
using adhesive seal. Mixing was achieved by shaking for 10 min, followed by two-hour 
incubation at 65 °C. Samples (in a volume of 75 μL) were brought to 80% ACN (v/v) by adding 
300 μL of ACN (J.T. Baker, Phillipsburg, NJ, USA). Free label and reducing agent were 
removed from the samples using HILIC-SPE. To each well of a 0.45 μm GHP filter plate (Pall 
Corporation, Ann Arbor, MI, USA) 200 μL of 0.1 g/mL suspension of microcrystalline cellulose 
(Merck, Darmstadt, Germany) in water was added. Solvent was removed by application of 
vacuum using a vacuum manifold (Millipore Corporation, Billerica, MA, USA). All wells were 
prewashed using 5× 200 μL of water, followed by equilibration using 3× 200 μL of 
acetonitrile/water (80:20, v/v). The samples were loaded to the wells, which were subsequently 
washed 7× using 200 μL of acetonitrile/water (80:20, v/v). Glycans were eluted 2× with 100 μL 
of water and combined eluates were stored at −20 °C until usage. 
Hydrophilic Interaction Chromatography (HILIC)-UPLC - Fluorescently labelled N-
glycans were separated by hydrophilic interaction chromatography on Waters Acquity ultra-
performance liquid chromatography (UPLC) instrument (Milford, MA, USA) consisting of a 
quaternary solvent manager, sample manager and a fluorescence detector set with excitation and 
emission wavelengths of 250 and 428 nm, respectively. The instrument was under the control of 
Empower 2 software, build 2145 (Waters, Milford, MA, USA). Labelled N-glycans were 
separated on a Waters bridged ethylene hybrid (BEH) Glycan chromatography column, 150 × 
2.1 mm, 1.7 μm BEH particles, with 100 mM ammonium formate, pH 4.4, as solvent A and 
acetonitrile as solvent B. The separation method used a linear gradient of 70–53% acetonitrile 
(v/v) at flow rate of 0.561 ml/min in a 25 min analytical run. Samples were maintained at 5 °C 
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before injection, and the separation temperature was 25 °C. The system was calibrated using an 
external standard of hydrolysed and 2-AB labelled glucose oligomers from which the retention 
times for the individual glycans were converted to glucose units. Data processing was performed 
using an automatic processing method with a traditional integration algorithm after which each 
chromatogram was manually corrected to maintain the same intervals of integration for all the 
samples. The chromatograms were all separated in the same manner into 46 peaks (GP1-GP46) 
and the amount of glycans in each peak was expressed as % of total integrated area (Fig 1). 
 
Statistical analysis 
In order to remove experimental variation from measurements, normalisation and batch 
correction were performed on UPLC glycan data. Also, normalisation by total area was 
performed in which the peak area of each glycan peak was divided by the total area of the 
corresponding chromatogram. Prior to batch correction, normalized glycan measurements were 
log-transformed due to right skewness of their distributions and the multiplicative nature of batch 
effects. Batch correction was performed on log-transformed measurements using the ComBat 
method, in which the technical source of variation (which sample was analysed on which plate) 
was modelled as a batch covariate. To get measurements corrected for experimental noise, 
estimated batch effects were subtracted from log-transformed measurements. 
From the 46 directly measured glycan traits, 12 derived traits were calculated (Table 1). 
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Table 1. Twelve derived glycan traits calculated from 46 directly measured glycan traits. 
Structural feature Formula 
low branching LB = GP1+GP2+GP3+GP4+GP5+GP6+GP7+GP8+GP9+GP10+GP11+GP12+GP13+GP14+GP15+GP16+GP17+ 
GP18+GP19+GP20+GP21+GP22+GP23+GP24+GP25+GP26+GP27+GP28 
high branching HB = 
GP29+GP30+GP31+GP32+GP33+GP34+GP35+GP36+GP37+GP38+GP39+GP40+GP41+GP42+GP43+GP44+GP45+G
P46 
agalactosylated G0 = GP1+GP2+GP4+GP5+GP6 
monogalactosylated G1 = GP3+GP7+GP8+GP9+GP10+GP16+GP17+GP18 
digalactosylated G2 = GP12+GP13+GP14+GP15+GP19+GP20+GP21+GP22+GP23+GP25+GP26+GP27+GP28 
trigalactosylated G3 = GP29+GP31+GP32+GP33+GP34+GP35+GP36+GP37+GP40 
tetragalactosylated G4 = GP30+GP38+GP39+GP41+GP42+GP43+GP44+GP45+GP46 
neutral S0 = GP1+GP2+GP3+GP4+GP5+GP6+GP7+GP8+GP9+GP10+GP11+GP12+GP13+GP14+GP15 
monosialylated S1 = GP16+GP17+GP18+GP19+GP20+GP21+GP22+GP30 
disialylated S2 = GP23+GP25+GP26+GP27+GP28+GP29+GP31 
trisialylated S3 = GP32+GP33+GP34+GP35+GP36+GP37+GP38+GP39+GP40 
tetrasialylated S4 = GP41+GP42+GP43+GP44+GP45+GP46 
 
These derived traits average particular glycosylation features (branching, galactosylation, 
sialylation) across different individual glycan structures, and consequently they are more closely 
related to individual enzymatic activities and underlying genetic polymorphisms. As derived 
traits represent sums of directly measured glycans, they were calculated using normalized and 
batch-corrected glycan measurements after transformation to the proportions (exponential 
transformation of batch-corrected measurements). 
Analyses of associations between clinical trait of interest (AcuteInflammation and 
AcuteInflammation Replication - hyperglycaemia;  FinRisk Cohort - future onset of diabetes; 
ORCADES & SABRE Cohorts - HbA1C > 6.5 % (47.5 mmol/mol)) and glycan measurements 
were performed using a regression model with age and sex included as additional covariates. 
Prior to analyses, for each cohort separately, glycan variables were transformed to a standard 
normal distribution by inverse transformation of ranks to normality. Using rank-transformed 
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variables makes estimated effects of different glycans in different cohorts comparable, as 
transformed glycan variables have the same standardized variance. The false discovery rate 
(FDR) was controlled using the Benjamini-Hochberg procedure.  
Data were analysed and visualized using R programming language (version 3.0.1).  
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Results 
Analysis of plasma N-glycome composition in AcuteInflammation and AcuteInflammation 
Replication populations 
For each patient, N-glycans were released from plasma proteins, fluorescently labelled 
and analysed by HILIC-UPLC, a method that was demonstrated to be the best approach for 
reliable and reproducible quantitative glycan analysis [14]. This method separates plasma 
glycome into 46 chromatographic peaks, each containing a group of similar glycan structures. 
Individual glycan structures contained in each peak were characterized previously [15] and 
representative chromatogram with main structure present in each peak is shown in Fig 1.  
Next, we quantified each chromatographic peak (as % of the total N-glycome) and calculated 
derived traits (Table 1). These derived traits represent common biologically meaningful features 
(glycan branching, galactosylation and sialylation) shared among several measured glycans. 
Then we compared these traits between two groups of patients in two populations:  
1. Those who developed hyperglycaemia during ICU hospitalization due to acute condition 
and those who remained normoglycaemic during the same circumstances 
(AcuteInflammation population, Table 2) – for the analysis, plasma samples taken 6-8 
weeks after the hospital discharge were used, and meanwhile the absence of 
inflammatory process was also confirmed (acquired profiles thus represented basal N-
glycomes for each person); 
2. Those who developed hyperglycaemia after cardiac surgery due to acute inflammation 
and those who remained normoglycaemic after the surgery (AcuteInflammation 
Replication population, Table 2) – for the analysis, plasma samples taken on the day of 
the surgery, before the surgical procedure were used. 
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The development of hyperglycaemia during acute inflammation represents significantly 
higher risk for type 2 diabetes development [2, 3].  
Fig 2 and Table 3 show differences in abundance of derived structural features of plasma 
protein N-glycans in individuals who developed hyperglycaemia during acute condition and 
controls. Differences are shown as the effect sizes estimated based on logistic regression 
(logarithm of odds ratio). In AcuteInflammation population, six derived traits were significantly 
different between the two groups – patients who developed hyperglycaemia had decreased low 
branching (LB) and increased high branching (HB), increased tri- and tetragalactosylation (G3 
and G4), decreased neutral glycans (S0) and increased trisialylation (S3).  
The differences found in AcuteInflammation Replication population showed the same trend 
and similar magnitude of changes, as found in the AcuteInflammation population for almost all 
derived traits, except for digalactosylation (G2). However, none of them reached statistical 
significance. 
 
Analysis of plasma N-glycome composition in FinRisk populations 
Differences in plasma protein N-glycome between individuals who will or will not 
develop type 2 diabetes was further valuated in the FinRisk study cohort, in which plasma 
samples were collected more than 10 years ago and biobanked. The 10-year follow-up has been 
performed to note the incidence of type 2 diabetes. Thirty-seven individuals who developed type 
2 diabetes and no other chronic disease and 37 age and sex matching controls, who remained 
healthy during follow-up period, were identified and included in the study. Plasma N-glycome 
was analysed in the same way as for the previous two populations.  
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Individuals who developed type 2 diabetes had significantly decreased LB and increased 
HB, decreased agalactosylation and monogalactosylation (G0 and G1), decreased neutral glycans 
(S0) and increased di- and tri-sialylation (S2 and S3), compared to individuals who remained 
normoglycaemic (Fig 2 and Table 3). For all derived glycan traits, differences found in FinRisk 
were in the same direction and of similar magnitude, as found in AcuteInflammation population. 
Analysis of plasma N-glycome composition in ORCADES and SABRE populations 
To further prove the connection of N-glycome with glucose metabolism disruption, we 
used data from our previous analysis of plasma protein glycosylation in two other cohorts 
(ORCADES and SABRE), where we separated age- and sex-matched individuals into two 
subgroups differing in HbA1c status (HbA1c < 6.5 % (47.5 mmol/mol) and HbA1c > 6.5 % (47.5 
mmol/mol)). 
We compared the differences between the two subgroups in the same way as in the 
previous populations.  Levels of the majority of glycan features were significantly different 
between the studied subgroups (10 for ORCADES and 7 for SABRE) (Fig 2 and Table 3). Main 
differences were the same as in the previous populations - higher levels of branching, 
galactosylation and sialylation in their plasma protein N-glycomes. 
 
Conclusions 
Our results indicate that plasma protein N-glycome is changed in individuals with 
increased risk for type 2 diabetes development (AcuteInflammation and AcuteInflammation 
Replication populations), incident cases of type 2 diabetes collected at baseline (FinRisk 
population) and people with increased HbA1c (ORCADES and SABRE populations). Differences 
in plasma N-glycomes were the same in all three populations and included higher levels of 
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branching, galactosylation and sialylation. This suggests that the increased complexity of glycan 
structures represents the greater chance for diabetes type 2 development and is also associated 
with poorer regulation of blood glucose levels.   
One can only speculate whether these differences in plasma glycome are inborn and 
genetically conditioned, or glycosylation is affected by the pathophysiological mechanisms that 
occur very early at diabetes onset and manifest themselves in the changes of the plasma glycome 
composition due to high susceptibility of glycans to changes in the cell metabolism. A possible 
explanation for this higher branching could be that higher glycaemia leads to altered flux through 
the hexosamine pathway, which produces UDP-GlcNAc, the substrate for N-linked glycosylation 
[16]. Recently, it has also been shown that the hexosamine biosynthesis and GlcNAc salvage 
pathways contribute to glucose homeostasis through N-glycan branching on glucagon receptor 
[17]. 
Previous studies showed that multi-branched and highly sialylated N-glycans were also 
elevated in response to inflammatory diseases, such as ulcerative colitis [18], chronic pancreatitis 
[19] and rheumatoid arthritis [20]. It is also well known that individuals with the metabolic 
syndrome and type 2 diabetes suffer from chronic low-grade inflammation [21]. Therefore, the 
N-glycan changes that were observed in this study may also reflect the chronic inflammatory 
processes. Additional support for this hypothesis comes from our recent study of a NMR 
biomarker GlycA and total plasma protein N-glycome. GlycA is a signal that measures N-
acetylglucosamines attached to the plasma proteins and it has been shown to correlate with wide 
spectra of inflammatory diseases, including incident type 2 diabetes mellitus [22, 23]. In that 
study we found that GlycA signal was positively related to highly branched structures, as well as 
tri- and tetragalactosylated and tri- and tetrasialylated structures, while low branched glycans, 
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agalactosylated, monogalactosylated, asialylated and monosialylated structures were negatively 
associated with GlycA signal [24]. These changes are practically the same as found herein, 
which suggests that the changes in plasma protein N-glycome could indicate the start of chronic 
inflammation and the susceptibility for developing the metabolic syndrome. This could also 
explain why the differences in derived glycan traits between the cases and controls in 
AcuteInflammation Replication population did not reach the threshold of significance – all 
individuals from this population had cardiovascular diseases and underwent cardiac surgery. 
Therefore, it is possible that most of them (both cases and controls) already had some kind of 
chronic inflammation. The other possible reason for this could be that the control group was too 
small (14 individuals). 
Despite the fact that we measured the whole plasma protein N-glycome, which is 
comprised of different glycans originating from many different glycoproteins, we managed to 
find differences in glycan traits between the controls and seemingly healthy individuals, who 
have a higher chance or will develop type 2 diabetes mellitus.  The same changes were also 
associated with poorer regulation of blood glucose. Identifying the exact glycoproteins which 
contribute to these differences would probably help to develop stratification methods that could 
reliably distinguish individuals who are at risk of type 2 diabetes development and improve the 
prevention of this widespread disease and its complications.   
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Figure legends 
 
 
Figure 1. HILIC-UPLC profile of N-linked glycans released from plasma proteins and 
fluorescently labelled with 2-aminobezamide. Glycans presented are the most abundant 
structures in each peak. Structural schemes: square, N-acetylglucosamine; triangle, fucose; dark 
grey circle, mannose; light grey circle, galactose; diamond, N-acetylneuraminic acid. 
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Figure 2. Differences in abundance of structural features of plasma protein N-glycans in 
individuals who developed hyperglycaemia during acute condition (AcuteInflammation and 
AcuteInflammation Replication populations - black and dark grey bars, respectively); in 
individuals from FinRisk population who developed type 2 diabetes during 10-year follow-up 
(light grey bars); in individuals from ORKNEY population (bars with horizontal stripes) and 
SABRE population (white bars) divided according to HbA1c level (< or > 6.5 % (47.5 
mmol/mol)). Pronounced differences were observed between cases and controls in all cohorts for 
several derived glycan structural features. Differences in derived glycan traits are shown as bar 
plots where height of bars represents the size of effects estimated based on logistic regression 
(logarithm of odds ratio) and error bars represent 95 % confidence intervals of estimated effects. 
(LB - low branching, sum of monoantennary and biantennary glycans, see Methods section; HB - 
high branching, sum of triantennary and tetraantennary glycans; G0 - sum of glycans with no 
galactose; G1 - sum of glycans with one galactose; G2 - sum of glycans with two galactoses; G3 
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- sum of glycans with three galactoses; G4 - sum of glycans with four galactoses; S0 - sum of 
glycans with no sialic acid; S1 - sum of glycans with one sialic acid; S2 - sum of glycans with 
two sialic acids; S3 - sum of glycans with three sialic acids; S4 - sum of glycans with four sialic 
acids; AI - AcuteInflammation; AI_R - AcuteInflammation Replication; FIN - FinRisk; ORK - 
ORKNEY; SAB - SABRE).  
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Tables 
Table 2. The demographic characteristics of AcuteInflammation and AcuteInflammation 
Replication populations. 
  All patients HG during acute illness No HG during acute illness  P value (HG vs. no HG)a 
Population AI AI_R  AI AI_R  AI AI_R  AI AI_R 
Number of patients (N) 108 66 59 52 49 14     
Age (y) 55 (18, 79) 67 (21, 81) 58 (25, 79) 68 (41, 81) 54 (18, 75) 62 (21, 78) 0.388 0.121 
Female sex (N,%) 32 (29.6%) 19 (28.8%) 18 (30.5%)  15 (28.8%) 14 (28.6%) 4 (28.6%) 0.826 0.984 
BMI (kg/m2) 23.7±4.0 28.2±3.5 24.2±4.1 28.5±3.4 23.1±3.9 27.2±3.8 0.734 0.342 
Family history of diabetes (N,%) 27 (25.0%) NA 19 (32.2%) NA 8 (16.3%) NA 0.039 NA 
 
(AI - AcuteInflammation; AI_R - AcuteInflammation Replication; HG - hyperglycaemia; BMI - body mass index; a P values 
were calculated using Mann-Whitney U test (significance level α=0.05) and for categorical variables Chi-square test was used)
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Table 3. Differences in derived structural features of plasma protein N-glycans between the cases and the controls in all five populations. Differences are shown as effects estimated based on 
logistic regression (logarithm of odds ratio).  
 
  AcuteInflammation AcuteInflammation_R FinRisk ORCADES SABRE 
derived 
 glycan trait 
effect SE P value adj. P value effect SE P value adj. P value effect SE P value adj. P value effect SE P value adj. P value effect SE P value adj. P value 
LB -0.480 0.179 0.006 0.016* -0.344 0.342 0.281 0.393 -0.517 0.230 0.022 0.040* -0.384 0.119 0.001 0.002** -0.284 0.077 0.000 0.001** 
HB 0.448 0.180 0.010 0.024* 0.344 0.342 0.281 0.393 0.517 0.230 0.022 0.040* 0.388 0.119 0.001 0.002** 0.339 0.077 0.000 0.000*** 
G0 -0.186 0.154 0.209 0.276 -0.023 0.327 0.940 0.956 -0.447 0.206 0.027 0.045* -0.276 0.113 0.014 0.019* -0.052 0.080 0.511 0.558 
G1 -0.359 0.184 0.044 0.068 -0.257 0.326 0.399 0.498 -0.603 0.225 0.007 0.017* -0.611 0.119 0.000 0.000*** -0.440 0.074 0.000 0.000*** 
G2 0.027 0.182 0.878 0.878 -0.312 0.332 0.314 0.428 0.250 0.217 0.236 0.290 0.036 0.118 0.759 0.759 0.097 0.079 0.213 0.276 
G3 0.399 0.163 0.011 0.024* 0.458 0.343 0.153 0.236 0.459 0.230 0.041 0.066 0.403 0.118 0.001 0.002** 0.403 0.076 0.000 0.000*** 
G4 0.406 0.190 0.027 0.045* 0.099 0.335 0.750 0.818 0.198 0.234 0.381 0.446 0.276 0.120 0.021 0.025* 0.024 0.079 0.756 0.789 
S0 -0.413 0.167 0.011 0.024* -0.271 0.332 0.380 0.487 -0.630 0.221 0.004 0.012* -0.455 0.119 0.000 0.001*** -0.297 0.077 0.000 0.001*** 
S1 -0.091 0.196 0.627 0.669 -0.581 0.310 0.047 0.083 -0.171 0.224 0.429 0.478 -0.354 0.120 0.003 0.005** -0.096 0.080 0.230 0.290 
S2 0.298 0.174 0.077 0.111 0.468 0.329 0.129 0.204 0.565 0.226 0.011 0.024* 0.547 0.120 0.000 0.000*** 0.327 0.077 0.000 0.000*** 
S3 0.517 0.181 0.003 0.010* 0.252 0.341 0.428 0.514 0.525 0.230 0.020 0.039* 0.358 0.121 0.003 0.005** 0.319 0.077 0.000 0.000*** 
S4 0.331 0.204 0.093 0.128 0.038 0.333 0.902 0.933 0.209 0.229 0.347 0.416 0.195 0.122 0.106 0.115 0.063 0.079 0.424 0.478 
 
(LB - low branching, sum of monoantennary and biantennary glycans, see Methods section; HB - high branching, sum of triantennary and tetraantennary glycans; G0 - sum of glycans with no galactose; G1 - sum of glycans with one galactose; G2 - sum of 
glycans with two galactoses; G3 - sum of glycans with three galactoses; G4 - sum of glycans with four galactoses; S0 - sum of glycans with no sialic acid; S1 - sum of glycans with one sialic acid; S2 - sum of glycans with two sialic acids; S3 - sum of 
glycans with three sialic acids; S4 - sum of glycans with four sialic acids; SE - standard error; adj. P value – P value corrected for multiple measures using Benjamini-Hochberg procedure; *P < 0.05, **P < 0.01, ***P < 0.001) 
